FDA grants Breakthrough Therapy status to PKC412 (midostaurin)
19 February 2016 | By Victoria White
PKC412 (midostaurin) is an investigational treatment for adults with newly-diagnosed acute myeloid leukaemia who are FLT3 mutation-positive...
List view / Grid view
News
Acelity partners with Mediq to strengthen its offering in Europe
19 February 2016 | By Victoria White
Acelity has announced a partnership with Mediq to exclusively distribute Acelity’s advanced wound care and regenerative medicine portfolio in Denmark, Finland, Norway and Sweden.
Celgene announces 72-week study results for ozanimod in MS
18 February 2016 | By Victoria White
Reductions in brain lesions at week 24 were maintained while relapses were further reduced at week 72 with continuous ozanimod treatment...
Yusen Logistics UK launches direct own consolidation services from UK to China
Yusen Logistics UK (YLUK) has launched a direct ‘Less than Container Load’ (LCL) own consolidation service from Southampton, UK to Shanghai, China.
Eye care company Alcon acquires Transcend Medical
18 February 2016 | By Victoria White
This Transcend Medical acquisition also expands Alcon's leadership in glaucoma and cataract treatment...
Diabetes drug pioglitazone may prevent recurring strokes
18 February 2016 | By Victoria White
A new study has found that pioglitazone may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes...
PerkinElmer Signals™ Perspectives launches in collaboration with Attivio
18 February 2016 | By PerkinElmer Inc
New data discovery solution leverages Attivio’s platform to provide insight into complex scientific challenges...
NICE calls for more research into Alexion’s sebelipase alfa
18 February 2016 | By Victoria White
NICE has published draft guidance that recommends further clinical trials are carried out to demonstrate the benefits sebelipase alfa for treating LAL deficiency...
inABLE® technology helps unlock the secrets of cyclic peptides
17 February 2016 | By Ingenza Laboratory
Ingenza is using its proprietary inABLE® technology to help develop a robust, versatile platform for the production of cyclic peptides for therapeutic use...
Praxbind (idarucizumab) reimbursed in England, Ireland and Wales
17 February 2016 | By Victoria White
Praxbind (idarucizumab) is now available to be used commercially after the Health Technology Appraisal bodies agreed that it is eligible for full reimbursment without the need for a full appraisal.
New study to investigate PQR309 and eribulin in triple-negative breast cancer
17 February 2016 | By Victoria White
Eisai and PIQUR Therapeutics are to collaborate to conduct the Phase I/IIb clinical study of PIQUR’s PQR309 in combination with Eisai’s eribulin...
Breakthrough Therapy Designation for ocrelizumab in PPMS
17 February 2016 | By Victoria White
Roche's ocrelizumab is the first investigational medicine to receive Breakthrough Therapy Designation in multiple sclerosis...
ICR scientists develop Ecosystem Diversity Index for breast cancers
16 February 2016 | By Victoria White
Scientists have developed a test called the Ecosystem Diversity Index which combines methods used by ecologists with a powerful cancer imaging technique...
FDA accepts Teflaro sNDA for filing
16 February 2016 | By Victoria White
If approved, this filing will expand the label of Teflaro beyond adults to include the treatment of children two months of age and older...
‘Extraordinary’ t-cell therapy results could change the face of cancer treatment
16 February 2016 | By Victoria White
In one study, the engineered T-cells induced complete remission in 94% of patients with acute lymphoblastic leukaemia...
